FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107300149> ?p ?o ?g. }

• W3107300149 endingPage "92" @default.
• W3107300149 startingPage "92" @default.
• W3107300149 abstract "The oligometastatic paradigm postulates that patients with a limited number of metastases can be treated with ablative local therapy to each site of disease with curative intent. Stereotactic ablative radiotherapy (SABR) is a radiation technique that has become widely used in this setting. However, prospective data are limited and are mainly from single institutional studies.To conduct a meta-analysis to characterize the safety and clinical benefit of SABR in oligometastatic cancer.A comprehensive search was conducted in PubMed/MEDLINE, Embase, Cochrane Database of Systematic Reviews, and Cumulative Index to Nursing and Allied Health Literature on December 23, 2019, that included prospective clinical trials and review articles that were published within the past 15 years.Inclusion criteria were single-arm or multiarm prospective trials including patients with oligometastatic cancer (ie, ≤5 sites of extracranial disease), and SABR was administered in less than or equal to 8 fractions with greater than or equal to 5 Gy/fraction.The Population, Intervention, Control, Outcomes and Study Design; Preferred Reporting Items for Systematic Reviews and Meta-analyses; and Meta-analysis of Observational Studies in Epidemiology methods were used to identify eligible studies. Study eligibility and data extraction were reviewed by 3 authors independently. Random-effects meta-analyses using the Knapp-Hartung correction, arcsine transformation, and restricted maximum likelihood method were conducted.Safety (acute and late grade 3-5 toxic effects) and clinical benefit (1-year local control, 1-year overall survival, and 1-year progression-free survival).Twenty-one studies comprising 943 patients and 1290 oligometastases were included. Median age was 63.8 years (interquartile range, 59.6-66.1 years) and median follow-up was 16.9 months (interquartile range, 13.7-24.5 months). The most common primary sites were prostate (22.9%), colorectal (16.6%), breast (13.1%), and lung (12.8%). The estimate for acute grade 3 to 5 toxic effect rates under the random-effects models was 1.2% (95% CI, 0%-3.8%; I2 = 50%; 95% CI, 3%-74%; and τ = 0.20%; 95% CI, 0.00%-1.43%), and the estimate for late grade 3 to 5 toxic effects was 1.7% (95% CI, 0.2%-4.6%; I2 = 54%; 95% CI, 11%-76%; and τ = 0.25%; 0.01%-1.00%). The random-effects estimate for 1-year local control was 94.7% (95% CI, 88.6%-98.6%; I2 = 90%; 95% CI, 86%-94%; and τ = 0.81%; 95% CI, 0.36%-2.38%]). The estimate for 1-year overall survival was 85.4% (95% CI, 77.1%-92.0%; I2 = 82%; 95% CI, 71%-88%; and τ = 0.72%; 95% CI, 0.30%-2.09%) and 51.4% (95% CI, 42.7%-60.1%; I2 = 58%; 95% CI, 17%-78%; and τ = 0.20%; 95% CI, 0.02%-1.21%) for 1-year progression-free survival.In this meta-analysis, SABR appears to be relatively safe in patients with oligometastatic cancer with clinically acceptable rates of acute and late grade 3 to 5 toxic effects less than 13% and with clinically acceptable rates of 1-year local control overall survival, and progression-free survival. These findings are hypothesis generating and require validation by ongoing and planned prospective clinical trials." @default.
• W3107300149 created "2020-12-07" @default.
• W3107300149 creator A5007734319 @default.
• W3107300149 creator A5026631408 @default.
• W3107300149 creator A5048702442 @default.
• W3107300149 creator A5067298210 @default.
• W3107300149 creator A5071389166 @default.
• W3107300149 creator A5078402900 @default.
• W3107300149 creator A5083566572 @default.
• W3107300149 creator A5083886265 @default.
• W3107300149 creator A5085787232 @default.
• W3107300149 creator A5091828411 @default.
• W3107300149 date "2021-01-01" @default.
• W3107300149 modified "2023-10-02" @default.
• W3107300149 title "Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer" @default.
• W3107300149 cites W1528207664 @default.
• W3107300149 cites W1572319397 @default.
• W3107300149 cites W1581492120 @default.
• W3107300149 cites W1589157904 @default.
• W3107300149 cites W1970241016 @default.
• W3107300149 cites W1976411156 @default.
• W3107300149 cites W1979423827 @default.
• W3107300149 cites W1997889941 @default.
• W3107300149 cites W2015003595 @default.
• W3107300149 cites W2025000901 @default.
• W3107300149 cites W2031688279 @default.
• W3107300149 cites W2033052459 @default.
• W3107300149 cites W2044990567 @default.
• W3107300149 cites W2049605916 @default.
• W3107300149 cites W2055407227 @default.
• W3107300149 cites W2092923243 @default.
• W3107300149 cites W2126852509 @default.
• W3107300149 cites W2126930838 @default.
• W3107300149 cites W2134852288 @default.
• W3107300149 cites W2137602317 @default.
• W3107300149 cites W2138398573 @default.
• W3107300149 cites W2139168999 @default.
• W3107300149 cites W2143853878 @default.
• W3107300149 cites W2148199505 @default.
• W3107300149 cites W2165322374 @default.
• W3107300149 cites W2166459387 @default.
• W3107300149 cites W2170356223 @default.
• W3107300149 cites W2293494611 @default.
• W3107300149 cites W2315123323 @default.
• W3107300149 cites W2335763958 @default.
• W3107300149 cites W2464924628 @default.
• W3107300149 cites W2468996569 @default.
• W3107300149 cites W2761351587 @default.
• W3107300149 cites W2775321189 @default.
• W3107300149 cites W2777272045 @default.
• W3107300149 cites W2797282777 @default.
• W3107300149 cites W2800535531 @default.
• W3107300149 cites W2801911503 @default.
• W3107300149 cites W2811260982 @default.
• W3107300149 cites W2885675882 @default.
• W3107300149 cites W2888635398 @default.
• W3107300149 cites W2889446552 @default.
• W3107300149 cites W2890381929 @default.
• W3107300149 cites W2894682456 @default.
• W3107300149 cites W2899682336 @default.
• W3107300149 cites W2904930609 @default.
• W3107300149 cites W2917696006 @default.
• W3107300149 cites W2939770857 @default.
• W3107300149 cites W2961998542 @default.
• W3107300149 cites W2975424845 @default.
• W3107300149 cites W2983766010 @default.
• W3107300149 cites W2997721110 @default.
• W3107300149 cites W3009016370 @default.
• W3107300149 cites W3013251573 @default.
• W3107300149 cites W3019546741 @default.
• W3107300149 cites W3032651552 @default.
• W3107300149 cites W4232184817 @default.
• W3107300149 cites W4234749243 @default.
• W3107300149 cites W4239112513 @default.
• W3107300149 cites W4240340450 @default.
• W3107300149 doi "https://doi.org/10.1001/jamaoncol.2020.6146" @default.
• W3107300149 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7689573" @default.
• W3107300149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33237270" @default.
• W3107300149 hasPublicationYear "2021" @default.
• W3107300149 type Work @default.
• W3107300149 sameAs 3107300149 @default.
• W3107300149 citedByCount "94" @default.
• W3107300149 countsByYear W31073001492021 @default.
• W3107300149 countsByYear W31073001492022 @default.
• W3107300149 countsByYear W31073001492023 @default.
• W3107300149 crossrefType "journal-article" @default.
• W3107300149 hasAuthorship W3107300149A5007734319 @default.
• W3107300149 hasAuthorship W3107300149A5026631408 @default.
• W3107300149 hasAuthorship W3107300149A5048702442 @default.
• W3107300149 hasAuthorship W3107300149A5067298210 @default.
• W3107300149 hasAuthorship W3107300149A5071389166 @default.
• W3107300149 hasAuthorship W3107300149A5078402900 @default.
• W3107300149 hasAuthorship W3107300149A5083566572 @default.
• W3107300149 hasAuthorship W3107300149A5083886265 @default.
• W3107300149 hasAuthorship W3107300149A5085787232 @default.
• W3107300149 hasAuthorship W3107300149A5091828411 @default.
• W3107300149 hasBestOaLocation W31073001492 @default.
• W3107300149 hasConcept C106159729 @default.

• next